Pharmacotherapics Advice in Guidelines for COVID-19

Pharmacotherapics Advice in Guidelines for COVID-19

Jin Liu, Jian Zhou, Ying Zhou, Lili Liu, Xiaohua Wei, Jinhua Wen, Zhangren Chen, Hongwei Peng, Haili Zhong, Ming-Fang Lai

Since December 2019 to May 2020, coronavirus disease 2019 (COVID-19) has infected over 6 million people worldwide. Due to its sudden and rapid outbreak, effective treatment for COVID-19 is scarce. Based on national clinical trials of novel treatments, China, Italy, Germany, and other countries and organizations have published multiple guidelines for COVID-19 and advised many medicines, such as chloroquine and tocilizumab. In this paper, we summarize the pharmacotherapy for COVID-19 according to those guidelines, highlight updates of the pharmacotherapy guidelines, and review the efficacy and safety of the indicated anti-COVID-19 drugs.

2020

Pneumonia, Pharmacotherapy, guideline, SARS-CoV-2, COVID-19

DOI: 10.3389/fphar.2020.00950

Frontiers in Pharmacology

Frontiers Media S.A.

Therapeutics. Pharmacology